<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>Springer New York</PublisherName>
    <PublisherLocation>New York, NY</PublisherLocation>
    <PublisherImprintName>Springer</PublisherImprintName>
  </PublisherInfo>
  <Book Language="En">
    <BookInfo BookProductType="Contributed volume" ContainsESM="No" Language="En" MediaType="eBook" NumberingStyle="ChapterOnly" OutputMedium="All" TocLevels="0">
      <BookID>978-1-60327-829-4</BookID>
      <BookTitle>Drug Management of Prostate Cancer</BookTitle>
      <BookDOI>10.1007/978-1-60327-829-4</BookDOI>
      <BookTitleID>158057</BookTitleID>
      <BookPrintISBN>978-1-60327-831-7</BookPrintISBN>
      <BookElectronicISBN>978-1-60327-829-4</BookElectronicISBN>
      <BookChapterCount>37</BookChapterCount>
      <BookCopyright>
        <CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName>
        <CopyrightYear>2010</CopyrightYear>
      </BookCopyright>
      <BookSubjectGroup>
        <BookSubject Code="SCH" Type="Primary">Medicine &amp; Public Health</BookSubject>
        <BookSubject Code="SCH33160" Priority="1" Type="Secondary">Oncology</BookSubject>
        <BookSubject Code="SCH62002" Priority="2" Type="Secondary">Urology</BookSubject>
        <BookSubject Code="SCH33002" Priority="3" Type="Secondary">Internal Medicine</BookSubject>
        <SubjectCollection Code="SUCO11650">Medicine</SubjectCollection>
      </BookSubjectGroup>
    </BookInfo>
    <BookHeader>
      <EditorGroup>
        <Editor AffiliationIDS="AffID1">
          <EditorName DisplayOrder="Western">
            <GivenName>William D.</GivenName>
            <FamilyName>Figg</FamilyName>
          </EditorName>
          <Contact>
            <Phone>301402-3622</Phone>
            <Fax>301402-8606</Fax>
            <Email>wdfigg@helix.nih.gov</Email>
          </Contact>
        </Editor>
        <Editor AffiliationIDS="AffID2">
          <EditorName DisplayOrder="Western">
            <GivenName>Cindy H.</GivenName>
            <FamilyName>Chau</FamilyName>
          </EditorName>
          <Contact>
            <Email>chauc@mail.nih.gov</Email>
          </Contact>
        </Editor>
        <Editor AffiliationIDS="AffID3">
          <EditorName DisplayOrder="Western">
            <GivenName>Eric J.</GivenName>
            <FamilyName>Small</FamilyName>
          </EditorName>
          <Contact>
            <Phone>415/353-7171</Phone>
            <Email>smalle@medicine.ucsf.edu</Email>
          </Contact>
        </Editor>
        <Affiliation ID="AffID1">
          <OrgDivision>Medical Oncology Branch</OrgDivision>
          <OrgName>NIH National Cancer Institute</OrgName>
          <OrgAddress>
            <Street>Rockville Pike 9000</Street>
            <City>Bethesda</City>
            <Postcode>20892</Postcode>
            <State>Maryland</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
        <Affiliation ID="AffID2">
          <OrgDivision>Medical Oncology Branch</OrgDivision>
          <OrgName>NIH National Cancer Institute</OrgName>
          <OrgAddress>
            <Street>Rockville Pike 9000</Street>
            <City>Bethesda</City>
            <Postcode>20892</Postcode>
            <State>Maryland</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
        <Affiliation ID="AffID3">
          <OrgDivision>School of Medicine, Dept. Urology</OrgDivision>
          <OrgName>University of California, San Francisco</OrgName>
          <OrgAddress>
            <Street>Divisadero Street 1600</Street>
            <City>San Francisco</City>
            <Postcode>94115</Postcode>
            <State>California</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
      </EditorGroup>
    </BookHeader>
    <Part ID="Part8">
      <PartInfo OutputMedium="All" TocLevels="0">
        <PartID>8</PartID>
        <PartNumber>Part VII</PartNumber>
        <PartSequenceNumber>8</PartSequenceNumber>
        <PartTitle>Drug Development</PartTitle>
        <PartChapterCount>3</PartChapterCount>
        <PartContext>
          <BookID>978-1-60327-829-4</BookID>
          <BookTitle>Drug Management of Prostate Cancer</BookTitle>
        </PartContext>
      </PartInfo>
      <Chapter ID="Chap34" Language="En">
        <ChapterInfo ChapterType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="ChapterOnly" OutputMedium="All" TocLevels="0">
          <ChapterID>34</ChapterID>
          <ChapterNumber>Chapter 34</ChapterNumber>
          <ChapterDOI>10.1007/978-1-60327-829-4_34</ChapterDOI>
          <ChapterSequenceNumber>34</ChapterSequenceNumber>
          <ChapterTitle Language="En">Challenges for the Development of New Agents in Prostate Cancer</ChapterTitle>
          <ChapterFirstPage>389</ChapterFirstPage>
          <ChapterLastPage>397</ChapterLastPage>
          <ChapterCopyright>
            <CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName>
            <CopyrightYear>2010</CopyrightYear>
          </ChapterCopyright>
          <ChapterHistory>
            <RegistrationDate>
              <Year>2010</Year>
              <Month>4</Month>
              <Day>16</Day>
            </RegistrationDate>
            <OnlineDate>
              <Year>2010</Year>
              <Month>8</Month>
              <Day>3</Day>
            </OnlineDate>
          </ChapterHistory>
          <ChapterGrants Type="Regular">
            <MetadataGrant Grant="OpenAccess"/>
            <AbstractGrant Grant="OpenAccess"/>
            <BodyPDFGrant Grant="Restricted"/>
            <BodyHTMLGrant Grant="Restricted"/>
            <BibliographyGrant Grant="Restricted"/>
            <ESMGrant Grant="Restricted"/>
          </ChapterGrants>
          <ChapterContext>
            <PartID>8</PartID>
            <BookID>978-1-60327-829-4</BookID>
            <BookTitle>Drug Management of Prostate Cancer</BookTitle>
          </ChapterContext>
        </ChapterInfo>
        <ChapterHeader>
          <AuthorGroup>
            <Author>
              <AuthorName DisplayOrder="Western">
                <GivenName>Ajjai</GivenName>
                <GivenName>S.</GivenName>
                <FamilyName>Alva</FamilyName>
              </AuthorName>
            </Author>
            <Author>
              <AuthorName DisplayOrder="Western">
                <GivenName>Deborah</GivenName>
                <GivenName>A.</GivenName>
                <FamilyName>Bradley</FamilyName>
              </AuthorName>
            </Author>
            <Author AffiliationIDS="Aff1_34" CorrespondingAffiliationID="Aff1_34">
              <AuthorName DisplayOrder="Western">
                <GivenName>Maha</GivenName>
                <FamilyName>Hussain</FamilyName>
              </AuthorName>
              <Contact>
                <Email>mahahuss@umich.edu</Email>
              </Contact>
            </Author>
            <Affiliation ID="Aff1_34">
              <OrgDivision>Comprehensive Cancer Center</OrgDivision>
              <OrgName>University of Michigan</OrgName>
              <OrgAddress>
                <City>Ann Arbor</City>
                <State>MI</State>
                <Country>USA</Country>
              </OrgAddress>
            </Affiliation>
          </AuthorGroup>
          <Abstract ID="Abs1_34" Language="En" OutputMedium="All">
            <Heading>Abstract</Heading>
            <Para TextBreak="No">Development of novel therapeutic agents in advanced prostate cancer presents particular challenges due to multiple factors including advanced age at diagnosis with competing causes of death and difficulties in assessing responses in bone (the predominant site of metastatic disease). Over the last 2 decades, few non hormonal drugs have met the regulatory requirements for approval in advanced prostate cancer. These include mitoxantrone (1996), zoledronic acid (2002) and docetaxel (2004). Sipuleucel-T, an autologous cell based vaccine and cabazitaxel were approved in 2010. Despite these breakthroughs, the general landscape for new and effective treatments in prostate cancer remains challenging. The aim of this review is to discuss the specific obstacles in the development of novel agents in prostate cancer and potential strategies to overcome them.</Para>
          </Abstract>
          <KeywordGroup Language="En" OutputMedium="All">
            <Heading>Keywords</Heading>
            <Keyword>Prostate cancer</Keyword>
            <Keyword>Novel targeted agents</Keyword>
            <Keyword>Challenges</Keyword>
            <Keyword>End-points</Keyword>
            <Keyword>Drug development</Keyword>
          </KeywordGroup>
        </ChapterHeader>
        <Body>
          <Section1 ID="Sec1" Type="Introduction">
            <Heading>Introduction</Heading>
            <Para TextBreak="No">Prostate cancer is a major public health problem. Despite the reported reduction in prostate cancer mortality, in 2008, over 28,000 men are destined to die from their disease [<CitationRef CitationID="CR1_34">1</CitationRef>]. The primary cause of mortality is metastatic castration-resistant prostate cancer (CRPC). Historically, few treatment options were available to this group of patients. However, a paradigm shift occurred when palliation was demonstrated with mitoxantrone therapy in the mid 1990s [<CitationRef CitationID="CR1_34">1</CitationRef>, <CitationRef CitationID="CR2_34">2</CitationRef>] followed by a modest but unequivocal survival benefit with docetaxel-based chemotherapy in two pivotal phase III trials in 2004 [<CitationRef CitationID="CR3_34">3</CitationRef>, <CitationRef CitationID="CR4_34">4</CitationRef>], a major advance in a disease once thought to be chemoresistant.</Para>
            <Para TextBreak="No">Over the last several years, a great deal of progress has been made in understanding prostate cancer biology leading to a plethora of new agents being investigated in first, second, and even third-line settings. Trial designs and modestly active agents in the context of a complex disease make approval of new agents difficult.</Para>
            <Para TextBreak="No">The difficulties in conducting clinical trials in prostate cancer are not new. Historically, several attempts were made to address the issue of screening for antitumor activity by enrolling only patients with measurable disease or looking at alternative endpoints [<CitationRef CitationID="CR2_34">2</CitationRef>–<CitationRef CitationID="CR4_34">4</CitationRef>]. However, based on disappointing trial results, several reviews, decades ago, concluded that chemotherapy had no real role in treatment of prostate cancer [<CitationRef CitationID="CR5_34">5</CitationRef>–<CitationRef CitationID="CR7_34">7</CitationRef>]. Several features of the disease and the patient population continue to present challenges in the development of new agents for this disease. Prostate cancer is a complex disease with marked inter and intrapatient heterogeneity, both at a clinical and molecular level [<CitationRef CitationID="CR8_34">8</CitationRef>]. Prostate cancer patients are generally older, with confounding comorbidities, and the disease manifests mostly in bone which is a difficult organ to assess. Second- and third-line hormone therapies are widely prevalent and their ease of use coupled with the desire to minimize toxicities owing to older age and patient comorbidities may play a role in delaying enrollment in clinical trials. Despite all these issues, the results of several recent trials clearly indicate that when an active agent is combined with adequate trial design, it is possible to obtain positive clinically meaningful results as reflected by phase III trials that led to FDA approval of mitoxantrone, zoledronic acid, and docetaxel [<CitationRef CitationID="CR9_34">9</CitationRef>–<CitationRef CitationID="CR14_34">14</CitationRef>].</Para>
          </Section1>
          <Section1 ID="Sec2">
            <Heading>Defining Appropriate Clinical Endpoints Based on Stage of Development</Heading>
            <Section2 ID="Sec3">
              <Heading>Screening for Antitumor Effect: “The Phase II Setting”</Heading>
              <Section3 ID="Sec4">
                <Heading>Objective Response: How Defined?</Heading>
                <Para TextBreak="No">For agents to make it to a phase III trial, it must be established with reasonable certainty that an agent has antitumor activity. With few exceptions, the latter, historically, has been based on measurable disease response in the vast majority of solid tumors. This poses a problem in prostate cancer in that even in the contemporary era, only 30–40% of patients have measurable soft tissue disease [<CitationRef CitationID="CR9_34">9</CitationRef>, <CitationRef CitationID="CR10_34">10</CitationRef>]. Therefore, limiting accrual to patients with measurable disease is neither practical nor reflective of the disease population at large. It is instructive, however, to note that with the taxanes, particularly docetaxel, evidence of significant objective antitumor activity was evident early in its development as reflected by measurable disease response in 28–55% of patients with an impressive median survival of up to 23 months [<CitationRef CitationID="CR15_34">15</CitationRef>–<CitationRef CitationID="CR18_34">18</CitationRef>]. This data was compelling and led to phase III testing [<CitationRef CitationID="CR9_34">9</CitationRef>, <CitationRef CitationID="CR10_34">10</CitationRef>]. Similarly, more recently measurable disease responses were also noted with ixabepilone [<CitationRef CitationID="CR19_34">19</CitationRef>, <CitationRef CitationID="CR20_34">20</CitationRef>].</Para>
                <Para TextBreak="No">Objective measurable disease response is clearly useful if present, however, for the vast majority of patients with metastatic prostate cancer; alternatives including better assessment of response in bone are needed. With better assessments lacking, one useful measure for screening for antitumor activity in CRPC, at least with use of cytotoxic therapy, has been PSA response. The role of PSA as an indicator of response was first reported in 1989 [<CitationRef CitationID="CR21_34">21</CitationRef>]. Following that report, several phase II trials utilized PSA as a marker of response [<CitationRef CitationID="CR22_34">22</CitationRef>–<CitationRef CitationID="CR24_34">24</CitationRef>]. Retrospective analyses of phase II trials suggested a correlation between a 50% or greater decline in PSA and survival [<CitationRef CitationID="CR23_34">23</CitationRef>, <CitationRef CitationID="CR25_34">25</CitationRef>, <CitationRef CitationID="CR26_34">26</CitationRef>] leading to a consensus recommendation by the Prostate-Specific Antigen Working Group [<CitationRef CitationID="CR27_34">27</CitationRef>] for use of PSA as an outcome measure in clinical trials. However, controversy remains regarding the optimum posttreatment PSA percentage decline, time for PSA evaluation in relationship to initiation of treatment, duration of posttreatment PSA decline, and definition of PSA progression. Retrospective analysis of several large clinical trials with known primary outcomes and PSA data available have helped to provide information related to PSA changes and prognosis (discussed below).</Para>
              </Section3>
              <Section3 ID="Sec5">
                <Heading>Time-to-Event End Points</Heading>
                <Para TextBreak="No">One key objective of therapy is better control of the disease activity (to delay disease progression) with the aim of reducing disease-related morbidities and maximizing quality of life. Clinically, this is meaningful to patients. Recognizing that response is one element of the control process and driven by the development of agents that may not exert an overt cytotoxic effect or have mechanisms of action that are cytostatic, efforts have focused on using time to progression (TTP) or progression-free survival (PFS) as the primary endpoints to capture antitumor effect. These endpoints have been successfully utilized in a variety of cancers where it also led to FDA approvals. An example in the genitourinary arena is sorafenib’s FDA approval based on improvement in PFS in renal cell carcinoma [<CitationRef CitationID="CR28_34">28</CitationRef>, <CitationRef CitationID="CR29_34">29</CitationRef>]. Of note is that if response rate was the driving factor, this drug would not have made it this far as it is associated with an objective response rate of less than 5% [<CitationRef CitationID="CR28_34">28</CitationRef>, <CitationRef CitationID="CR29_34">29</CitationRef>].</Para>
              </Section3>
              <Section3 ID="Sec6">
                <Heading>Challenges in Using Time-to-Event Endpoints in CRPC</Heading>
                <Para TextBreak="No">TTP does not incorporate death, while PFS includes progression and death from any cause. Both are appealing, but challenging. The challenges in evaluating PFS and TTP are similar. Ideally, trials should be controlled and blinded, progression must be prospectively defined, and plans to handle missing data must be prospectively determined. Timing of tumor assessments must be symmetrical in all study arms. If progression is to be determined radiographically, independent radiology review may be ideal for the analysis and interpretation of trial results, though may not be practical and is costly for phase II settings.</Para>
                <Para TextBreak="No">Because bone is the predominant site of disease and often the only site of disease in patients with metastatic prostate cancer, ability to assess response in bone plays a major role in time-to-event endpoints. Response of bone lesions in clinical trials has been based on radionuclide bone scans. Although considered to be the standard screening technique for assessing the entire skeleton for metastases, it is well recognized that bone scanning lacks the specificity needed to accurately assess response vs. flare. These limitations stem from the fact that bone scans measure only osteoblastic metabolic activity and do not evaluate structural integrity of bone nor actual growth nor apoptosis of the cancer cells themselves.</Para>
                <Para TextBreak="No">The problem of assessing response in bone has been well illustrated in development of atrasentan, an endothelin antagonist, hypothesized to interfere with the development and progression of osteoblastic bone metastases [<CitationRef CitationID="CR30_34">30</CitationRef>–<CitationRef CitationID="CR33_34">33</CitationRef>] in prostate cancer. Results of a double-blind, randomized, placebo-controlled, multinational phase II trial [<CitationRef CitationID="CR34_34">34</CitationRef>] investigating two dose levels of atrasentan showed a nonsignificant trend towards an increase in TTP with a significant increase in time to PSA progression in patients treated with atrasentan. In this trial, bone scans were only done at baseline and at progression. Interim bone scan assessments were not mandated per protocol. Based on the phase II trial results, a phase III trial compared TTP between atrasentan and placebo. Bone scans were performed as part of the efficacy analysis every 12 weeks. The study was closed early by an Independent Data Safety Monitoring Committee after reviewing an unexpectedly high number of early progressions. Of note, &gt;50% of patients reached the progression endpoint within 100 days of trial entry, mostly due to bone scan progressions. Intention to treat analysis of the 809 patients accrued prior to trial closure showed a nonsignificant trend towards an increase in TTP favoring the atrasentan arm [<CitationRef CitationID="CR35_34">35</CitationRef>, <CitationRef CitationID="CR36_34">36</CitationRef>]. When the analysis was limited to patients with bone metastases, a significant increase in TTP was observed [<CitationRef CitationID="CR35_34">35</CitationRef>, <CitationRef CitationID="CR36_34">36</CitationRef>]. In review, the study that mandated bone scans showed early radiologic progression in the absence of clinical symptoms in most patients raising concern whether response was appropriately assessed given the limitations of bone scans.</Para>
                <Para TextBreak="No">As a result of this trial and others, a recent update to consensus recommendations for clinical trial conduct in advanced prostate cancer (Prostate Cancer Working Group 2) was published [<CitationRef CitationID="CR37_34">37</CitationRef>]. The key change in these recommendations is to focus on time-to-event measures rather than response and to ensure adequate drug exposure before declaring futility.</Para>
              </Section3>
            </Section2>
            <Section2 ID="Sec7">
              <Heading>The Phase III Setting</Heading>
              <Para TextBreak="No">The gold standard in assessing clinical benefit of anticancer therapies in prostate cancer as well as other malignancies has been survival outcomes assessed in prospective randomized phase III trials. Although necessary, these trials are costly, requiring large numbers of patients often followed over many years. Survival has proven to be an achievable endpoint in metastatic CRPC [<CitationRef CitationID="CR9_34">9</CitationRef>, <CitationRef CitationID="CR10_34">10</CitationRef>]. However, whenever survival is the measure in a trial where a large number of trial participants have a disease with a relatively long natural history, the observed results maybe confounded by competing causes of mortality, and subsequent treatment. This has not been a critical issue in this stage of the disease, though it is very relevant in earlier stages of prostate cancer.</Para>
              <Section3 ID="Sec8">
                <Heading>Patient-Reported Outcomes</Heading>
                <Para TextBreak="No">Patient-reported outcomes such as symptom benefit are clinically important and have served as an endpoint for drug approval. Several problems confound the assessment of symptoms of advanced prostate cancer, including the fact that the symptoms of this disease often overlap with intercurrent conditions and older age and side effects of therapy. Therefore, any efficacy with respect to patient reported outcome can only be established by conducting randomized, controlled, double-blinded trials with a prospectively defined primary endpoint using validated measuring instruments, analysis methodology, and a clinically meaningful effect size.</Para>
                <Para TextBreak="No">Patient-reported outcomes led to approval of mitoxantrone, in combination with prednisone for the treatment of metastatic CRPC patients with pain related to disease. Its efficacy was demonstrated in an open-label phase III trial of 161 symptomatic patients that used prospectively defined endpoint of palliative response. Twenty-nine percent of the patients in the mitoxantrone + prednisone arm, compared to 12% in the prednisone alone arm, demonstrated a two-point improvement on a six-point pain intensity scale that was at least 6 weeks in duration, and was accompanied by a stable analgesic score [<CitationRef CitationID="CR11_34">11</CitationRef>].</Para>
                <Para TextBreak="No">Although this endpoint provides direct evidence of clinical benefit to patients, it has not been correlated with improvement in survival; optimal tools have not yet been defined, and many methodological problems remain unresolved, therefore is rarely used as a primary endpoint for assessing drug efficacy today. Patient-related outcomes have also become of more limited value because patients with metastatic CRPC enrolling in clinical trials today are often asymptomatic or have few symptoms attributable to disease. This is in stark contrast to the 80s and 90s when most patients presented with advanced clinically morbid disease.</Para>
              </Section3>
              <Section3 ID="Sec9">
                <Heading>Composite Endpoints</Heading>
                <Para TextBreak="No">No single ideal endpoint has been described yet in this disease that is suitable for all disease stages and drugs. A composite endpoint can be appropriate when the benefit of a drug is multifaceted. In metastatic prostate cancer, zoledronic acid was approved for treatment of patients with progressive bone metastases using a composite endpoint [<CitationRef CitationID="CR13_34">13</CitationRef>, <CitationRef CitationID="CR14_34">14</CitationRef>]. In this phase III trial, 643 men with asymptomatic or minimally symptomatic CRPC and evidence of bone metastases were randomized to zoledronic acid or placebo. The endpoint was occurrence of any skeletal-related event at 15 months as defined by pathological fracture, spinal cord compression, surgery, or radiation therapy to bone or change in antineoplastic treatment for bone pain. At 15 months, patients treated with zoledronic acid experienced fewer skeletal-related events as compared to patients treated with placebo (33 vs. 44%, <Emphasis Type="Italic">P</Emphasis> = 0.02). Results of this study led to FDA approval of zoledronic acid in patients with CRPC with bone metastases.</Para>
                <Para TextBreak="No">More recently, a composite endpoint was utilized to investigate satraplatin, a novel orally bioavailable platinum compound, in the second line setting for men with CRPC. In a large multinational randomized phase III trial comparing satraplatin plus prednisone to placebo plus prednisone, the Satraplatin and Prednisone Against Refractory Cancer (SPARC) trial, a coprimary endpoint of overall survival and PFS (defined as a composite endpoint based on first occurrence of tumor progression, skeletal event, symptomatic progression, or death) was utilized. Secondary and exploratory endpoints included time to pain progression, pain response, tumor response, and PSA response. Final results of this 950 patient trial have been presented [<CitationRef CitationID="CR38_34">38</CitationRef>, <CitationRef CitationID="CR39_34">39</CitationRef>]. A 33% improvement in PFS in favor of satraplatin was reported (11.1 vs. 9.7 weeks and HR 0.67 95% CI 0.57–0.77; <Emphasis Type="Italic">P</Emphasis> &lt; 0.0001), but no benefit in overall survival was demonstrated (61.3 vs. 61.4 week andHR = 0.97; 95% CI 0.83–1.13). All other prespecified endpoints were statistically significant in favor of satraplatin. Of interest, a significant number of patients went on to receive third-line chemotherapy. It is doubtful that further treatment can explain the lack of a survival benefit considering there is no effective third-line therapy.</Para>
              </Section3>
            </Section2>
          </Section1>
          <Section1 ID="Sec10">
            <Heading>Use of Alternative Clinical Endpoints</Heading>
            <Para TextBreak="No">Development of surrogate endpoints that can be objectively measured and lead to a quicker determination of whether an agent is of benefit or not to patients is an area of active investigation and significant interest in prostate cancer research.</Para>
            <Section2 ID="Sec11">
              <Heading>Biomarkers</Heading>
              <Para TextBreak="No">A biomarker is a characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention [<CitationRef CitationID="CR40_34">40</CitationRef>]. There has been significant interest in use of biomarkers as surrogates in clinical trials. In order for a biomarker to qualify as a valid surrogate endpoint, (1) the biomarker must be a prognostic marker of the true clinical endpoint, (2) treatment-mediated changes in the potential surrogate must be prognostic, and (3) effects of treatments on the marker must be associated with effects of treatments on the true clinical endpoint [<CitationRef CitationID="CR41_34">41</CitationRef>].</Para>
            </Section2>
            <Section2 ID="Sec12">
              <Heading>PSA</Heading>
              <Para TextBreak="No">PSA has served as a biomarker for diagnosis, prognosis and monitoring for disease activity, and response to therapy in different settings of prostate cancer. The observation that systemic and local therapies impact the PSA level has led to the use of PSA in the daily clinical practice to guide therapeutic decisions. This clearly impacts on the integrity of clinical trials that have harder clinical endpoints, not to mention, causing difficulties when reconciling PSA changes with objective disease measures when they are in opposite directions. To date, there are no data from prospective randomized clinical trials that have validated these practices to produce level one supporting evidence. Despite this, given the limitations of studies with overt clinical endpoints, with the reproducible and quantitative nature of PSA, enormous interest has been focused on developing and evaluating PSA-based endpoints.</Para>
            </Section2>
            <Section2 ID="Sec13">
              <Heading>PSA Response</Heading>
              <Para TextBreak="No">The role of PSA decline as an indicator of response in CRPC was first reported in 1989 [<CitationRef CitationID="CR21_34">21</CitationRef>]. Following this report, several phase II trials utilized PSA as a marker of antitumor response with retrospective analyses suggesting a correlation between a 50% or greater decline in PSA and survival [<CitationRef CitationID="CR23_34">23</CitationRef>, <CitationRef CitationID="CR25_34">25</CitationRef>, <CitationRef CitationID="CR26_34">26</CitationRef>]. In 1999, recommendations by the Prostate-Specific Antigen Working Group [<CitationRef CitationID="CR27_34">27</CitationRef>] were published. These aimed at streamlining design and outcome reporting for phase II clinical trials in prostate cancer. PSA decline was suggested as one outcome measure. However, controversy remains regarding the optimum posttreatment PSA percentage decline in relation to baseline PSA, time for PSA evaluation in relation to initiation of treatment, duration of posttreatment PSA decline, and definition of PSA progression. Retrospective analysis of several large clinical trials with known primary outcomes and PSA data available have helped to provide information related to PSA changes and prognosis such that specific PSA endpoints can be validated in prospective trials.</Para>
              <Para TextBreak="No">In newly metastatic disease treated with androgen deprivation therapy (ADT), the PSA level after 7 months of ADT strongly correlated with risk of death in a secondary analysis of the first 1.345 patients registered to SWOG 9346 (INT-0162) [<CitationRef CitationID="CR42_34">42</CitationRef>]. In this phase III trial, hormone naïve patients with metastatic disease were treated 7 months of induction ADT. Patients who achieved a PSA of 4.0 ng/mL or less on months 6 and 7 were randomized to continuous vs. intermitted ADT. After controlling for prognostic factors, patients with a PSA of 4 or less to more than 0.2 ng/mL had less than one-third the risk of death as those with a PSA of more than 4 ng/mL (<Emphasis Type="Italic">P</Emphasis>&lt; 0.001). Patients with PSA of 0.2 ng/mL or less had less than one-fifth the risk of death as patients with a PSA of more than 4 ng/mL (<Emphasis Type="Italic">P</Emphasis>&lt; 0.001) and had significantly better survival than those with PSA of more than 0.2–4 ng/mL or less (<Emphasis Type="Italic">P</Emphasis>&lt; 0.001). Median survival was 13 months for patients with a PSA of more than 4 ng/mL at the end of induction (95% CI, 11–16 months), 44 months for patients with PSA of more than 0.2–4 ng/mL or less (95% CI 39–55 months), and 75 months for patients with PSA of 0.2 ng/mL or less (95% CI 62–91 months) suggesting that PSA level at 7 months may be a useful endpoint in this patient population.</Para>
              <Para TextBreak="No">Secondary analysis of SWOG 9916, a randomized phase III trial comparing docetaxel and estramustine to mitoxantrone and prednisone in patients with metastatic CRPC evaluated PSA changes as potential surrogate markers for survival [<CitationRef CitationID="CR43_34">43</CitationRef>]. Three-month PSA level declines of 20–40%, a 2-month PSA decline of 30%, and PSA velocity at 2 and 3 months met the Prentice’s surrogacy criteria. The optimal biochemical surrogate was a 30% PSA decline 3 months after treatment initiation. A PSA decline of ≥30% within 3 months of chemotherapy initiation also had the highest degree of surrogacy in analysis of data from the TAX327 trial, a multinational phase III trial comparing different schedules of docetaxel and prednisone to mitoxantrone and prednisone in the same patient population, although surrogacy was more modest in this trial [<CitationRef CitationID="CR44_34">44</CitationRef>]. If validated, PSA decline as a surrogate endpoint in future trials has the potential to substantially alter the design and duration of future phase III studies. These findings are being prospectively confirmed in two randomized cooperative group trials (SWOG-0421 and CALGB 90401).</Para>
            </Section2>
            <Section2 ID="Sec14">
              <Heading>PSA Progression</Heading>
              <Para TextBreak="No">In hormone-sensitive and CRPC, PSA progression heralds clinical progression [<CitationRef CitationID="CR45_34">45</CitationRef>] and has been an accepted indicator of worsening disease, though no data exist regarding what constitutes an appropriate definition for PSA progression. So far criteria have been consensus-based [<CitationRef CitationID="CR27_34">27</CitationRef>, <CitationRef CitationID="CR37_34">37</CitationRef>]. Several definitions including definitions proposed by the Prostate-Specific Antigen Working Group [<CitationRef CitationID="CR27_34">27</CitationRef>] and the Prostate Cancer Working Group [<CitationRef CitationID="CR37_34">37</CitationRef>] were recently explored using PSA data from two SWOG trials with hormone sensitive (S9346) and CRPC (S9916) [<CitationRef CitationID="CR46_34">46</CitationRef>]. The Prostate-Specific Antigen Working Group 1999 and the Prostate Cancer Working Group 2008 were both strongly predictive of overall survival indicating that both consensus definitions are useful. However, whether PSA progression or PSA response is a more useful endpoint to consider remains unanswered.</Para>
            </Section2>
            <Section2 ID="Sec15">
              <Heading>Limitations of PSA Based End-Points</Heading>
              <Para TextBreak="No">Although PSA endpoints have been are attractive to overcome some of the difficulties encountered in assessing outcome by means of other endpoints, e.g., bone scans or pain relief, it is not established how well the posttherapy PSA changes capture the biologic effect of therapy on the tumor. As described above, different PSA-based endpoints may correlate with disease prognosis, can thus support their use for patient selection and stratification in clinical trials, and may also provide evidence of activity of a drug in a Phase 2 trial. The data described above suggest a potential PSA role, however, routine application await prospective validation of PSA as a surrogate for clinical benefit. Because PSA changes can be drug class-specific and disease state-specific, its validation as a surrogate or intermediate marker needs to be established for each drug class and disease state combination. Pending prospective validation, however, several strong leads in different disease settings, discussed above, suggest that PSA may be a useful intermediate biomarker in some settings.</Para>
            </Section2>
            <Section2 ID="Sec16">
              <Heading>Biochemical Markers of Bone Turnover</Heading>
              <Para TextBreak="No">Biochemical markers of bone turnover can be classified as markers of bone resorption and bone formation reflecting osteoclastic and osteoblastic activity respectively. Originally used to evaluate treatment of metabolic bone disease, over the last several years, the potential utility of bone turnover to measure efficacy of bone targeted therapy in cancer has been realized [<CitationRef CitationID="CR13_34">13</CitationRef>, <CitationRef CitationID="CR47_34">47</CitationRef>, <CitationRef CitationID="CR48_34">48</CitationRef>]. Given that bone is the predominant site and often only site of disease in 85–90% of men with metastatic prostate cancer [<CitationRef CitationID="CR9_34">9</CitationRef>, <CitationRef CitationID="CR10_34">10</CitationRef>], the use of bone turnover markers to monitor therapy has been of particular interest in this disease. Although in prostate cancer, bone metastases are mostly osteoblastic in nature, it is well recognized that prostate cancer metastases result from a heterogeneous mixture of osetoblastic and osteolytic lesions [<CitationRef CitationID="CR49_34">49</CitationRef>–<CitationRef CitationID="CR52_34">52</CitationRef>]. It has been shown that osteoblastic metastases form on trabecular bone at sites of previous osteoclast resorption and that such resorption is required for subsequent osteoblastic bone formation [<CitationRef CitationID="CR53_34">53</CitationRef>, <CitationRef CitationID="CR54_34">54</CitationRef>]. These findings suggest that prostate cancer induces bone production through an overall increase in bone remodeling [<CitationRef CitationID="CR55_34">55</CitationRef>–<CitationRef CitationID="CR57_34">57</CitationRef>]; thus, investigation of markers of osteoblastic and osteoclastic activity are relevant in evaluating baseline disease activity and monitoring therapeutic response.</Para>
              <Para TextBreak="No">In prostate cancer, investigation of bone turnover markers has largely been limited to studies of bisphosphonate use. In this setting, elevated markers of osteolytic activity (N-telopeptide) and osteoblastic activity (bone-specific alkaline phosphatase) have been associated with adverse clinical outcomes including shorter time to skeletal events, disease progression, and death [<CitationRef CitationID="CR13_34">13</CitationRef>, <CitationRef CitationID="CR47_34">47</CitationRef>, <CitationRef CitationID="CR48_34">48</CitationRef>]. Additionally, a correlation between baseline values of N-telopeptide, bone-specific alkaline phosphatase, PSA, and number of bone lesions have also been shown [<CitationRef CitationID="CR48_34">48</CitationRef>, <CitationRef CitationID="CR58_34">58</CitationRef>], suggesting baseline markers of osteolytic and osteoblastic activity correlate with tumor burden. There is little data published on the effect of chemotherapy on bone makers. This is in large part secondary to the ability of PSA to serve as a surrogate of response in traditional cytoxic therapies. However, as the potential treatment armamentarium available has increased to include targeted therapeutics that may not be cytotoxic, standard clinical endpoints of efficacy such as tumor response rates may not be as applicable as they are. Therefore, the role of bone turnover markers is again being investigated to aid in assessing treatment response, especially in bone targeted therapy [<CitationRef CitationID="CR34_34">34</CitationRef>, <CitationRef CitationID="CR59_34">59</CitationRef>–<CitationRef CitationID="CR61_34">61</CitationRef>]. Results from phase II and III studies of atrasentan, an investigational agent that inhibits the endothelin-A receptor resulting in decreased osteoblast activity, has shown no significant responses as assessed by classical measures, yet it appeared to result in an increase in TTP in patients with bone metastatses [<CitationRef CitationID="CR5_34">5</CitationRef>, <CitationRef CitationID="CR6_34">6</CitationRef>, <CitationRef CitationID="CR40_34">40</CitationRef>]. Investigation of bone markers in these studies has also demonstrated suppression of biochemical markers of bone turnover supporting the potential role of bone turnover markers in investigating efficacy of novel agents. Clearly for bone turnover markers to be of use as a response measure, their role must be first validated. To do so, changes in bone turnover marker have been included as a secondary endpoint in S0241, a phase III trial investigating the addition of atrasentan to docetaxel + prednisone.</Para>
            </Section2>
            <Section2 ID="Sec17">
              <Heading>Circulating Tumor Cells</Heading>
              <Para TextBreak="No">Other biomarkers being evaluated include circulating tumor cells (CTC). CTCs have been demonstrated in multiple solid tumors and have been of clinical interest for several decades. Recent technology advances with improved sensitivity and specificity have made it feasible to measure and characterize CTCs leading to resurgence into their investigation. The largest body of knowledge utilizing CTCs to monitor treatment response comes from the breast cancer literature. Cristofanelli et al. have shown that number of CTCs before treatment is an independent predictor of PFS and overall survival in patients with metastatic breast cancer [<CitationRef CitationID="CR62_34">62</CitationRef>] and that detection of elevated CTCs during therapy is an accurate indication of rapid disease progression and mortality [<CitationRef CitationID="CR63_34">63</CitationRef>]. Recent studies in CRPC are evaluating the ability of CTCs to be used as a surrogate of overall survival. Moreno et al. investigated CTCs in peripheral blood of CRPC patients pre and posttherapy [<CitationRef CitationID="CR64_34">64</CitationRef>]. At every time point, including baseline, patients with less than 5 CTCs/7.5 mL had a significantly improved overall survival compared to those with more than 5 CTCs. Patients who had a reduction in CTCs to less than 5 CTCs/7.5 mL at 2–5 weeks after treatment had significantly improved survival compared to those who had persistently high CTCs. Multivariate analyses of the 240 evaluable patients in this study revealed CTC number as the strongest independent predictor of outcome. The Cellsearch <Superscript>TM</Superscript> system used in the above study has been granted an expanded clearance by the FDA for monitoring therapy in CRPC patients and is now commercially available. If validated in larger prospective trials, CTCs could serve as convenient and early indicators of treatment efficacy in trials of new agents or combination therapy in CRPC.</Para>
            </Section2>
          </Section1>
          <Section1 ID="Sec18" Type="Conclusion">
            <Heading>Conclusions</Heading>
            <Para TextBreak="No">The gold standard in assessing clinical benefit of anticancer therapies in prostate cancer, as well as other malignancies, has been survival outcomes assessed in prospective randomized phase III trials. Significant progress has been made over the last decade in understanding the biology of prostate cancer development and progression. As a result, most drugs chosen for study today are based on sound rationale, aimed at targeting specific biological changes thought to be crucial mediators in disease progression. However, with a plethora of targets identified and multiple promising agents available for investigation, the challenge now is how to prioritize to swiftly eliminate inactive or marginal agents and to enable promising therapies to be taken to definitive phase III clinical trials. To do this efficiently, alternative endpoints and tools that are applicable to the complex nature of this disease are necessary, particularly in the phase II setting so that a “go/no-go” decision can be made regarding an agent as to its worthiness of more definitive testing.</Para>
          </Section1>
        </Body>
        <BodyRef FileRef="BodyRef/PDF/978-1-60327-829-4_Chapter_34.pdf" OutputMedium="Online" PDFType="Typeset" TargetType="OnlinePDF"/>
        <ChapterBackmatter>
          <Bibliography ID="Bib1">
            <Heading>References</Heading>
            <Citation ID="CR1_34">
              <CitationNumber>1</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Jemal</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Siegel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Ward</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">Cancer statistics, 2008</ArticleTitle>
                <JournalTitle>CA Cancer J Clin</JournalTitle>
                <VolumeID>58</VolumeID>
                <FirstPage>71</FirstPage>
                <LastPage>96</LastPage>
                <Occurrence Type="PID">
                  <Handle>18287387</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.3322/CA.2007.0010</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71–96.</BibUnstructured>
            </Citation>
            <Citation ID="CR2_34">
              <CitationNumber>2</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JD</Initials>
                  <FamilyName>Schmidt</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RP</Initials>
                  <FamilyName>Gibbons</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DE</Initials>
                  <FamilyName>Johnson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GR</Initials>
                  <FamilyName>Prout</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WW</Initials>
                  <FamilyName>Scott</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GP</Initials>
                  <FamilyName>Murphy</FamilyName>
                </BibAuthorName>
                <Year>1976</Year>
                <ArticleTitle Language="En">Chemotherapy of advanced prostatic cancer. Evaluation of response parameters</ArticleTitle>
                <JournalTitle>Urology</JournalTitle>
                <VolumeID>7</VolumeID>
                <FirstPage>602</FirstPage>
                <LastPage>10</LastPage>
                <Occurrence Type="PID">
                  <Handle>936381</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/0090-4295(76)90085-6</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaE283isFOrtg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Schmidt JD, Gibbons RP, Johnson DE, Prout GR, Scott WW, Murphy GP. Chemotherapy of advanced prostatic cancer. Evaluation of response parameters. Urology 1976;7:602–10.</BibUnstructured>
            </Citation>
            <Citation ID="CR3_34">
              <CitationNumber>3</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>NH</Initials>
                  <FamilyName>Slack</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GP</Initials>
                  <FamilyName>Murphy</FamilyName>
                </BibAuthorName>
                <Year>1984</Year>
                <ArticleTitle Language="En">Criteria for evaluating patient responses to treatment modalities for prostatic cancer</ArticleTitle>
                <JournalTitle>Urol Clin North Am</JournalTitle>
                <VolumeID>11</VolumeID>
                <FirstPage>337</FirstPage>
                <LastPage>42</LastPage>
                <Occurrence Type="PID">
                  <Handle>6375069</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaL2c3isFCgtw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Slack NH, Murphy GP. Criteria for evaluating patient responses to treatment modalities for prostatic cancer. Urol Clin North Am 1984;11:337–42.</BibUnstructured>
            </Citation>
            <Citation ID="CR4_34">
              <CitationNumber>4</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>NH</Initials>
                  <FamilyName>Slack</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MF</Initials>
                  <FamilyName>Brady</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GP</Initials>
                  <FamilyName>Murphy</FamilyName>
                </BibAuthorName>
                <Year>1984</Year>
                <ArticleTitle Language="En">Stable versus partial response in advanced prostate cancer</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>5</VolumeID>
                <FirstPage>401</FirstPage>
                <LastPage>15</LastPage>
                <Occurrence Type="PID">
                  <Handle>6377284</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/pros.2990050405</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaL2c3kslOlsQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Slack NH, Brady MF, Murphy GP. Stable versus partial response in advanced prostate cancer. Prostate 1984;5:401–15.</BibUnstructured>
            </Citation>
            <Citation ID="CR5_34">
              <CitationNumber>5</CitationNumber>
              <BibUnstructured>Eisenberger MA. Chemotherapy for prostate carcinoma. NCI Monogr 1988;(7):151–63.</BibUnstructured>
            </Citation>
            <Citation ID="CR6_34">
              <CitationNumber>6</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Yagoda</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Petrylak</FamilyName>
                </BibAuthorName>
                <Year>1993</Year>
                <ArticleTitle Language="En">Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>71</VolumeID>
                <FirstPage>1098</FirstPage>
                <LastPage>109</LastPage>
                <Occurrence Type="PID">
                  <Handle>7679039</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/1097-0142(19930201)71:3+&lt;1098::AID-CNCR2820711432&gt;3.0.CO;2-G</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK3s7ltlOgsg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993;71:1098–109.</BibUnstructured>
            </Citation>
            <Citation ID="CR7_34">
              <CitationNumber>7</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>IF</Initials>
                  <FamilyName>Tannock</FamilyName>
                </BibAuthorName>
                <Year>1985</Year>
                <ArticleTitle Language="En">Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate?</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>3</VolumeID>
                <FirstPage>1013</FirstPage>
                <LastPage>21</LastPage>
                <Occurrence Type="PID">
                  <Handle>3894584</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaL2M3mtlOhsg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Tannock IF. Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate? J Clin Oncol 1985;3:1013–21.</BibUnstructured>
            </Citation>
            <Citation ID="CR8_34">
              <CitationNumber>8</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RB</Initials>
                  <FamilyName>Shah</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Mehra</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AM</Initials>
                  <FamilyName>Chinnaiyan</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>64</VolumeID>
                <FirstPage>9209</FirstPage>
                <LastPage>16</LastPage>
                <Occurrence Type="PID">
                  <Handle>15604294</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/0008-5472.CAN-04-2442</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXhtVOmsbzP</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Shah RB, Mehra R, Chinnaiyan AM, et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 2004;64:9209–16.</BibUnstructured>
            </Citation>
            <Citation ID="CR9_34">
              <CitationNumber>9</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DP</Initials>
                  <FamilyName>Petrylak</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CM</Initials>
                  <FamilyName>Tangen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MH</Initials>
                  <FamilyName>Hussain</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer</ArticleTitle>
                <JournalTitle>N Engl J Med</JournalTitle>
                <VolumeID>351</VolumeID>
                <FirstPage>1513</FirstPage>
                <LastPage>20</LastPage>
                <Occurrence Type="PID">
                  <Handle>15470214</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1056/NEJMoa041318</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXot1Kmu7c%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513–20.</BibUnstructured>
            </Citation>
            <Citation ID="CR10_34">
              <CitationNumber>10</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>IF</Initials>
                  <FamilyName>Tannock</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Wit</FamilyName>
                  <Particle>de</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WR</Initials>
                  <FamilyName>Berry</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer</ArticleTitle>
                <JournalTitle>N Engl J Med</JournalTitle>
                <VolumeID>351</VolumeID>
                <FirstPage>1502</FirstPage>
                <LastPage>12</LastPage>
                <Occurrence Type="PID">
                  <Handle>15470213</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1056/NEJMoa040720</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXot1Kmu7s%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502–12.</BibUnstructured>
            </Citation>
            <Citation ID="CR11_34">
              <CitationNumber>11</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>IF</Initials>
                  <FamilyName>Tannock</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Osoba</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MR</Initials>
                  <FamilyName>Stockler</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1996</Year>
                <ArticleTitle Language="En">Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>14</VolumeID>
                <FirstPage>1756</FirstPage>
                <LastPage>64</LastPage>
                <Occurrence Type="PID">
                  <Handle>8656243</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK28XjslOrsr8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996;14:1756–64.</BibUnstructured>
            </Citation>
            <Citation ID="CR12_34">
              <CitationNumber>12</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PW</Initials>
                  <FamilyName>Kantoff</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Halabi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Conaway</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1999</Year>
                <ArticleTitle Language="En">Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>17</VolumeID>
                <FirstPage>2506</FirstPage>
                <LastPage>13</LastPage>
                <Occurrence Type="PID">
                  <Handle>10561316</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXltlyltL8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999;17:2506–13.</BibUnstructured>
            </Citation>
            <Citation ID="CR13_34">
              <CitationNumber>13</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Saad</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DM</Initials>
                  <FamilyName>Gleason</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Murray</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2002</Year>
                <ArticleTitle Language="En">A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma</ArticleTitle>
                <JournalTitle>J Natl Cancer Inst</JournalTitle>
                <VolumeID>94</VolumeID>
                <FirstPage>1458</FirstPage>
                <LastPage>68</LastPage>
                <Occurrence Type="PID">
                  <Handle>12359855</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1093/jnci/94.19.1458</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XosVans7g%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458–68.</BibUnstructured>
            </Citation>
            <Citation ID="CR14_34">
              <CitationNumber>14</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Saad</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DM</Initials>
                  <FamilyName>Gleason</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Murray</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer</ArticleTitle>
                <JournalTitle>J Natl Cancer Inst</JournalTitle>
                <VolumeID>96</VolumeID>
                <FirstPage>879</FirstPage>
                <LastPage>82</LastPage>
                <Occurrence Type="PID">
                  <Handle>15173273</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1093/jnci/djh141</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXkvVSrurk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;96:879–82.</BibUnstructured>
            </Citation>
            <Citation ID="CR15_34">
              <CitationNumber>15</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DP</Initials>
                  <FamilyName>Petrylak</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Macarthur</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>O’Connor</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1999</Year>
                <ArticleTitle Language="En">Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer</ArticleTitle>
                <JournalTitle>Semin Oncol</JournalTitle>
                <VolumeID>26</VolumeID>
                <FirstPage>28</FirstPage>
                <LastPage>33</LastPage>
                <Occurrence Type="PID">
                  <Handle>10604266</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXivVahtQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Petrylak DP, Macarthur R, O’Connor J, et al. Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer. Semin Oncol 1999;26:28–33.</BibUnstructured>
            </Citation>
            <Citation ID="CR16_34">
              <CitationNumber>16</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DM</Initials>
                  <FamilyName>Savarese</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Halabi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>V</Initials>
                  <FamilyName>Hars</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>19</VolumeID>
                <FirstPage>2509</FirstPage>
                <LastPage>16</LastPage>
                <Occurrence Type="PID">
                  <Handle>11331330</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXjvVelurY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Savarese DM, Halabi S, Hars V, et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol 2001;19:2509–16.</BibUnstructured>
            </Citation>
            <Citation ID="CR17_34">
              <CitationNumber>17</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Kreis</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Budman</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">Daily oral estramustine and intermittent intravenous docetaxel (Taxotere) as chemotherapeutic treatment for metastatic, hormone-refractory prostate cancer</ArticleTitle>
                <JournalTitle>Semin Oncol</JournalTitle>
                <VolumeID>26</VolumeID>
                <FirstPage>34</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>10604267</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXivVahug%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kreis W, Budman D. Daily oral estramustine and intermittent intravenous docetaxel (Taxotere) as chemotherapeutic treatment for metastatic, hormone-refractory prostate cancer. Semin Oncol 1999;26:34–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR18_34">
              <CitationNumber>18</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DP</Initials>
                  <FamilyName>Petrylak</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RB</Initials>
                  <FamilyName>Macarthur</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>O’Connor</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1999</Year>
                <ArticleTitle Language="En">Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>17</VolumeID>
                <FirstPage>958</FirstPage>
                <LastPage>67</LastPage>
                <Occurrence Type="PID">
                  <Handle>10071290</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXhvFGgu7k%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Petrylak DP, Macarthur RB, O’Connor J, et al. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol 1999;17:958–67.</BibUnstructured>
            </Citation>
            <Citation ID="CR19_34">
              <CitationNumber>19</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MD</Initials>
                  <FamilyName>Galsky</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EJ</Initials>
                  <FamilyName>Small</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WK</Initials>
                  <FamilyName>Oh</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>23</VolumeID>
                <FirstPage>1439</FirstPage>
                <LastPage>46</LastPage>
                <Occurrence Type="PID">
                  <Handle>15735119</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2005.09.042</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXis1Gnu7Y%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Galsky MD, Small EJ, Oh WK, et al. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol 2005;23:1439–46.</BibUnstructured>
            </Citation>
            <Citation ID="CR20_34">
              <CitationNumber>20</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Hussain</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CM</Initials>
                  <FamilyName>Tangen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PN</Initials>
                  <FamilyName>Lara</FamilyName>
                  <Suffix>Jr</Suffix>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>23</VolumeID>
                <FirstPage>8724</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>16314632</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2005.02.4448</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hussain M, Tangen CM, Lara PN, Jr., et al. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. J Clin Oncol 2005;23:8724–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR21_34">
              <CitationNumber>21</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Ferro</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Gillatt</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MO</Initials>
                  <FamilyName>Symes</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PJ</Initials>
                  <FamilyName>Smith</FamilyName>
                </BibAuthorName>
                <Year>1989</Year>
                <ArticleTitle Language="En">High-dose intravenous estrogen therapy in advanced prostatic carcinoma. Use of serum prostate-specific antigen to monitor response</ArticleTitle>
                <JournalTitle>Urology</JournalTitle>
                <VolumeID>34</VolumeID>
                <FirstPage>134</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>2476882</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/0090-4295(89)90248-3</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaL1MzovFWqsw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Ferro MA, Gillatt D, Symes MO, Smith PJ. High-dose intravenous estrogen therapy in advanced prostatic carcinoma. Use of serum prostate-specific antigen to monitor response. Urology 1989;34:134–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR22_34">
              <CitationNumber>22</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AD</Initials>
                  <FamilyName>Seidman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HI</Initials>
                  <FamilyName>Scher</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Petrylak</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DD</Initials>
                  <FamilyName>Dershaw</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Curley</FamilyName>
                </BibAuthorName>
                <Year>1992</Year>
                <ArticleTitle Language="En">Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>147</VolumeID>
                <FirstPage>931</FirstPage>
                <LastPage>4</LastPage>
                <Occurrence Type="PID">
                  <Handle>1371564</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK387mslCmsQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Seidman AD, Scher HI, Petrylak D, Dershaw DD, Curley T. Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer. J Urol 1992;147:931–4.</BibUnstructured>
            </Citation>
            <Citation ID="CR23_34">
              <CitationNumber>23</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DC</Initials>
                  <FamilyName>Smith</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RL</Initials>
                  <FamilyName>Dunn</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MS</Initials>
                  <FamilyName>Strawderman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KJ</Initials>
                  <FamilyName>Pienta</FamilyName>
                </BibAuthorName>
                <Year>1998</Year>
                <ArticleTitle Language="En">Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>16</VolumeID>
                <FirstPage>1835</FirstPage>
                <LastPage>43</LastPage>
                <Occurrence Type="PID">
                  <Handle>9586898</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK1c3ks1eisg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Smith DC, Dunn RL, Strawderman MS, Pienta KJ. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol 1998;16:1835–43.</BibUnstructured>
            </Citation>
            <Citation ID="CR24_34">
              <CitationNumber>24</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RT</Initials>
                  <FamilyName>Vollmer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>NA</Initials>
                  <FamilyName>Dawson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>NJ</Initials>
                  <FamilyName>Vogelzang</FamilyName>
                </BibAuthorName>
                <Year>1998</Year>
                <ArticleTitle Language="En">The dynamics of prostate specific antigen in hormone refractory prostate carcinoma: an analysis of cancer and leukemia group B study 9181 of megestrol acetate</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>83</VolumeID>
                <FirstPage>1989</FirstPage>
                <LastPage>94</LastPage>
                <Occurrence Type="PID">
                  <Handle>9806658</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/(SICI)1097-0142(19981101)83:9&lt;1989::AID-CNCR15&gt;3.0.CO;2-V</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXntlCktL4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Vollmer RT, Dawson NA, Vogelzang NJ. The dynamics of prostate specific antigen in hormone refractory prostate carcinoma: an analysis of cancer and leukemia group B study 9181 of megestrol acetate. Cancer 1998;83:1989–94.</BibUnstructured>
            </Citation>
            <Citation ID="CR25_34">
              <CitationNumber>25</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>WK</Initials>
                  <FamilyName>Kelly</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HI</Initials>
                  <FamilyName>Scher</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Mazumdar</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>V</Initials>
                  <FamilyName>Vlamis</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Schwartz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SD</Initials>
                  <FamilyName>Fossa</FamilyName>
                </BibAuthorName>
                <Year>1993</Year>
                <ArticleTitle Language="En">Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>11</VolumeID>
                <FirstPage>607</FirstPage>
                <LastPage>15</LastPage>
                <Occurrence Type="PID">
                  <Handle>7683043</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK3s3ktVWrsA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kelly WK, Scher HI, Mazumdar M, Vlamis V, Schwartz M, Fossa SD. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 1993;11:607–15.</BibUnstructured>
            </Citation>
            <Citation ID="CR26_34">
              <CitationNumber>26</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>HI</Initials>
                  <FamilyName>Scher</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WM</Initials>
                  <FamilyName>Kelly</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ZF</Initials>
                  <FamilyName>Zhang</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1999</Year>
                <ArticleTitle Language="En">Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer</ArticleTitle>
                <JournalTitle>J Natl Cancer Inst</JournalTitle>
                <VolumeID>91</VolumeID>
                <FirstPage>244</FirstPage>
                <LastPage>51</LastPage>
                <Occurrence Type="PID">
                  <Handle>10037102</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1093/jnci/91.3.244</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK1M7lsVOjtA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Scher HI, Kelly WM, Zhang ZF, et al. Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer. J Natl Cancer Inst 1999;91:244–51.</BibUnstructured>
            </Citation>
            <Citation ID="CR27_34">
              <CitationNumber>27</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>GJ</Initials>
                  <FamilyName>Bubley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Carducci</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Dahut</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1999</Year>
                <ArticleTitle Language="En">Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>17</VolumeID>
                <FirstPage>3461</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>10550143</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD3c%2FhvValsg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999;17:3461–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR28_34">
              <CitationNumber>28</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>Ratain</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Eisen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WM</Initials>
                  <FamilyName>Stadler</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>24</VolumeID>
                <FirstPage>2505</FirstPage>
                <LastPage>12</LastPage>
                <Occurrence Type="PID">
                  <Handle>16636341</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2005.03.6723</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XmtVOmtrk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:2505–12.</BibUnstructured>
            </Citation>
            <Citation ID="CR29_34">
              <CitationNumber>29</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Escudier</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Eisen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WM</Initials>
                  <FamilyName>Stadler</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Sorafenib in advanced clear-cell renal-cell carcinoma</ArticleTitle>
                <JournalTitle>N Engl J Med</JournalTitle>
                <VolumeID>356</VolumeID>
                <FirstPage>125</FirstPage>
                <LastPage>34</LastPage>
                <Occurrence Type="PID">
                  <Handle>17215530</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1056/NEJMoa060655</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXksVKitg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125–34.</BibUnstructured>
            </Citation>
            <Citation ID="CR30_34">
              <CitationNumber>30</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JB</Initials>
                  <FamilyName>Nelson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SP</Initials>
                  <FamilyName>Hedican</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DJ</Initials>
                  <FamilyName>George</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1995</Year>
                <ArticleTitle Language="En">Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate</ArticleTitle>
                <JournalTitle>Nat Med</JournalTitle>
                <VolumeID>1</VolumeID>
                <FirstPage>944</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>7585222</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/nm0995-944</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2MXnvVyrtb8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Nelson JB, Hedican SP, George DJ, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995;1:944–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR31_34">
              <CitationNumber>31</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JJ</Initials>
                  <FamilyName>Yin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KS</Initials>
                  <FamilyName>Mohammad</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SM</Initials>
                  <FamilyName>Kakonen</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci U S A</JournalTitle>
                <VolumeID>100</VolumeID>
                <FirstPage>10954</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>12941866</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1073/pnas.1830978100</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXnslyntbg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Yin JJ, Mohammad KS, Kakonen SM, et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci U S A 2003;100:10954–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR32_34">
              <CitationNumber>32</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Pirtskhalaishvili</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JB</Initials>
                  <FamilyName>Nelson</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">Endothelium-derived factors as paracrine mediators of prostate cancer progression</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>44</VolumeID>
                <FirstPage>77</FirstPage>
                <LastPage>87</LastPage>
                <Occurrence Type="PID">
                  <Handle>10861760</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/1097-0045(20000615)44:1&lt;77::AID-PROS10&gt;3.0.CO;2-G</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXksVCru7k%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Pirtskhalaishvili G, Nelson JB. Endothelium-derived factors as paracrine mediators of prostate cancer progression. Prostate 2000;44:77–87.</BibUnstructured>
            </Citation>
            <Citation ID="CR33_34">
              <CitationNumber>33</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SG</Initials>
                  <FamilyName>Thakkar</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TK</Initials>
                  <FamilyName>Choueiri</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JA</Initials>
                  <FamilyName>Garcia</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Endothelin receptor antagonists: rationale, clinical development, and role in prostate cancer therapeutics</ArticleTitle>
                <JournalTitle>Curr Oncol Rep</JournalTitle>
                <VolumeID>8</VolumeID>
                <FirstPage>108</FirstPage>
                <LastPage>13</LastPage>
                <Occurrence Type="PID">
                  <Handle>16507220</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1007/s11912-006-0045-1</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28Xis1yiu7s%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Thakkar SG, Choueiri TK, Garcia JA. Endothelin receptor antagonists: rationale, clinical development, and role in prostate cancer therapeutics. Curr Oncol Rep 2006;8:108–13.</BibUnstructured>
            </Citation>
            <Citation ID="CR34_34">
              <CitationNumber>34</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Carducci</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RJ</Initials>
                  <FamilyName>Padley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Breul</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>21</VolumeID>
                <FirstPage>679</FirstPage>
                <LastPage>89</LastPage>
                <Occurrence Type="PID">
                  <Handle>12586806</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2003.04.176</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXpsVGrurY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Carducci MA, Padley RJ, Breul J, et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 2003;21:679–89.</BibUnstructured>
            </Citation>
            <Citation ID="CR35_34">
              <CitationNumber>35</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Lipton</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DJ</Initials>
                  <FamilyName>Sleep</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SM</Initials>
                  <FamilyName>Hulting</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JD</Initials>
                  <FamilyName>Isaacson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AR</Initials>
                  <FamilyName>Allen</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Benefit of atrasentan in men with hormone refractory prostate cancer metastatic to bone</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>22</VolumeID>
                <FirstPage>4687</FirstPage>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2004.11.084</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lipton A, Sleep DJ, Hulting SM, Isaacson JD, Allen AR. Benefit of atrasentan in men with hormone refractory prostate cancer metastatic to bone. J Clin Oncol 2004;22:4687.</BibUnstructured>
            </Citation>
            <Citation ID="CR36_34">
              <CitationNumber>36</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DJ</Initials>
                  <FamilyName>Sleep</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JB</Initials>
                  <FamilyName>Nelson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DP</Initials>
                  <FamilyName>Petrylak</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JD</Initials>
                  <FamilyName>Isaacson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Carducci</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Clinical benefit of atrasentan for men with metastatic hormone-refractory prostate cancer metastatic to bone</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>24</VolumeID>
                <FirstPage>4630</FirstPage>
              </BibArticle>
              <BibUnstructured>Sleep DJ, Nelson JB, Petrylak DP, Isaacson JD, Carducci MA. Clinical benefit of atrasentan for men with metastatic hormone-refractory prostate cancer metastatic to bone. J Clin Oncol 2006;24:4630.</BibUnstructured>
            </Citation>
            <Citation ID="CR37_34">
              <CitationNumber>37</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>HI</Initials>
                  <FamilyName>Scher</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Halabi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>I</Initials>
                  <FamilyName>Tannock</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>26</VolumeID>
                <FirstPage>1148</FirstPage>
                <LastPage>59</LastPage>
                <Occurrence Type="PID">
                  <Handle>18309951</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2007.12.4487</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26:1148–59.</BibUnstructured>
            </Citation>
            <Citation ID="CR38_34">
              <CitationNumber>38</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CN</Initials>
                  <FamilyName>Sternberg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Petrylak</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Witjes</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Satraplatin (S) demonstrates significant clinical benefits for the treatment of patients with HRPC: results of a randomized phase III trial</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>25</VolumeID>
                <FirstPage>5019</FirstPage>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2007.11.8711</Handle>
                </Occurrence>
                <BibComments>abstract</BibComments>
              </BibArticle>
              <BibUnstructured>Sternberg CN, Petrylak D, Witjes F, et al. Satraplatin (S) demonstrates significant clinical benefits for the treatment of patients with HRPC: results of a randomized phase III trial. J Clin Oncol 2007;25:abstract 5019.</BibUnstructured>
            </Citation>
            <Citation ID="CR39_34">
              <CitationNumber>39</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Sartor</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Petrylak</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Witjes</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">Satraplatin in patients with advanced hormone-refractory prostate cancer (HRPC): overall survival (OS) results from the phase III satraplatin and prednisone against refractory cancer (SPARC) trial</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>20</VolumeID>
                <FirstPage>5003</FirstPage>
                <BibComments>Suppl:abstract</BibComments>
              </BibArticle>
              <BibUnstructured>Sartor A, Petrylak D, Witjes J, et al. Satraplatin in patients with advanced hormone-refractory prostate cancer (HRPC): overall survival (OS) results from the phase III satraplatin and prednisone against refractory cancer (SPARC) trial. J Clin Oncol 2008;20 Suppl:abstract 5003.</BibUnstructured>
            </Citation>
            <Citation ID="CR40_34">
              <CitationNumber>40</CitationNumber>
              <BibArticle>
                <InstitutionalAuthorName>Biomarkers Definitions Working Group</InstitutionalAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Biomarkers and surrogate endpoints preferred definitions and conceptual framework</ArticleTitle>
                <JournalTitle>Clin Pharmacol Ther</JournalTitle>
                <VolumeID>69</VolumeID>
                <FirstPage>89</FirstPage>
                <LastPage>95</LastPage>
                <Occurrence Type="DOI">
                  <Handle>10.1067/mcp.2001.113989</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89–95.</BibUnstructured>
            </Citation>
            <Citation ID="CR41_34">
              <CitationNumber>41</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RL</Initials>
                  <FamilyName>Prentice</FamilyName>
                </BibAuthorName>
                <Year>1989</Year>
                <ArticleTitle Language="En">Surrogate endpoints in clinical trials: definition and operational criteria</ArticleTitle>
                <JournalTitle>Stat Med</JournalTitle>
                <VolumeID>8</VolumeID>
                <FirstPage>431</FirstPage>
                <LastPage>40</LastPage>
                <Occurrence Type="PID">
                  <Handle>2727467</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/sim.4780080407</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaL1M3ms1aktg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989;8:431–40.</BibUnstructured>
            </Citation>
            <Citation ID="CR42_34">
              <CitationNumber>42</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Hussain</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CM</Initials>
                  <FamilyName>Tangen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Higano</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162)</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>24</VolumeID>
                <FirstPage>3984</FirstPage>
                <LastPage>90</LastPage>
                <Occurrence Type="PID">
                  <Handle>16921051</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2006.06.4246</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hussain M, Tangen CM, Higano C, et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 2006;24:3984–90.</BibUnstructured>
            </Citation>
            <Citation ID="CR43_34">
              <CitationNumber>43</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DP</Initials>
                  <FamilyName>Petrylak</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DP</Initials>
                  <FamilyName>Ankerst</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CS</Initials>
                  <FamilyName>Jiang</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16</ArticleTitle>
                <JournalTitle>J Natl Cancer Inst</JournalTitle>
                <VolumeID>98</VolumeID>
                <FirstPage>516</FirstPage>
                <LastPage>21</LastPage>
                <Occurrence Type="PID">
                  <Handle>16622120</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1093/jnci/djj129</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Petrylak DP, Ankerst DP, Jiang CS, et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 2006;98:516–21.</BibUnstructured>
            </Citation>
            <Citation ID="CR44_34">
              <CitationNumber>44</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AJ</Initials>
                  <FamilyName>Armstrong</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Garrett-Mayer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>YC</Initials>
                  <FamilyName>Ou Yang</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>25</VolumeID>
                <FirstPage>3965</FirstPage>
                <LastPage>70</LastPage>
                <Occurrence Type="PID">
                  <Handle>17761981</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2007.11.4769</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Armstrong AJ, Garrett-Mayer E, Ou Yang YC, et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol 2007;25:3965–70.</BibUnstructured>
            </Citation>
            <Citation ID="CR45_34">
              <CitationNumber>45</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Eisenberger</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Crawford</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>McLeod</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Hussain</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Loehrer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Blumenstein</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1995</Year>
                <ArticleTitle Language="En">The prognostic significance of prostate specific antigen (PSA) in stage D2 prostate cancer (PC) interim evaluation of intergroup study 0105 (Meeting abstract)</ArticleTitle>
                <JournalTitle>Proceedings of the 1995 ASCO Annual Meeting</JournalTitle>
                <VolumeID>14</VolumeID>
                <FirstPage>613</FirstPage>
                <BibComments>abstract</BibComments>
              </BibArticle>
              <BibUnstructured>Eisenberger M, Crawford E, McLeod D, Hussain M, Loehrer P, Blumenstein B. The prognostic significance of prostate specific antigen (PSA) in stage D2 prostate cancer (PC) interim evaluation of intergroup study 0105 (Meeting abstract). Proceedings of the 1995 ASCO Annual Meeting 1995;14:abstract 613.</BibUnstructured>
            </Citation>
            <Citation ID="CR46_34">
              <CitationNumber>46</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Hussain</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Goldman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Tangen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Higano</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Petrylak</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Crawford</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">Use of prostate-specific antigen progression (PSA-P) to predict overall survival (OS) in patients (pts) with metastatic prostate cancer (PC): data from S9346 and S9916</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>20</VolumeID>
                <FirstPage>5015</FirstPage>
                <BibComments>Suppl:abstract</BibComments>
              </BibArticle>
              <BibUnstructured>Hussain M, Goldman B, Tangen C, Higano C, Petrylak D, Crawford E. Use of prostate-specific antigen progression (PSA-P) to predict overall survival (OS) in patients (pts) with metastatic prostate cancer (PC): data from S9346 and S9916. J Clin Oncol 2008;20 Suppl:abstract 5015.</BibUnstructured>
            </Citation>
            <Citation ID="CR47_34">
              <CitationNumber>47</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JE</Initials>
                  <FamilyName>Brown</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RJ</Initials>
                  <FamilyName>Cook</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Major</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors</ArticleTitle>
                <JournalTitle>J Natl Cancer Inst</JournalTitle>
                <VolumeID>97</VolumeID>
                <FirstPage>59</FirstPage>
                <LastPage>69</LastPage>
                <Occurrence Type="PID">
                  <Handle>15632381</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1093/jnci/dji002</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXisVarsA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005;97:59–69.</BibUnstructured>
            </Citation>
            <Citation ID="CR48_34">
              <CitationNumber>48</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RE</Initials>
                  <FamilyName>Coleman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Major</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Lipton</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>23</VolumeID>
                <FirstPage>4925</FirstPage>
                <LastPage>35</LastPage>
                <Occurrence Type="PID">
                  <Handle>15983391</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2005.06.091</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXpsFWmtL4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005;23:4925–35.</BibUnstructured>
            </Citation>
            <Citation ID="CR49_34">
              <CitationNumber>49</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>ET</Initials>
                  <FamilyName>Keller</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Brown</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Prostate cancer bone metastases promote both osteolytic and osteoblastic activity</ArticleTitle>
                <JournalTitle>J Cell Biochem</JournalTitle>
                <VolumeID>91</VolumeID>
                <FirstPage>718</FirstPage>
                <LastPage>29</LastPage>
                <Occurrence Type="PID">
                  <Handle>14991763</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/jcb.10662</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXitlGisL4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Keller ET, Brown J. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J Cell Biochem 2004;91:718–29.</BibUnstructured>
            </Citation>
            <Citation ID="CR50_34">
              <CitationNumber>50</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Berruti</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Piovesan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Torta</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1996</Year>
                <ArticleTitle Language="En">Biochemical evaluation of bone turnover in cancer patients with bone metastases: relationship with radiograph appearances and disease extension</ArticleTitle>
                <JournalTitle>Br J Cancer</JournalTitle>
                <VolumeID>73</VolumeID>
                <FirstPage>1581</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>8664134</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/bjc.1996.298</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK283mt1Wntw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Berruti A, Piovesan A, Torta M, et al. Biochemical evaluation of bone turnover in cancer patients with bone metastases: relationship with radiograph appearances and disease extension. Br J Cancer 1996;73:1581–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR51_34">
              <CitationNumber>51</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Vinholes</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Coleman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Eastell</FamilyName>
                </BibAuthorName>
                <Year>1996</Year>
                <ArticleTitle Language="En">Effects of bone metastases on bone metabolism: implications for diagnosis, imaging and assessment of response to cancer treatment</ArticleTitle>
                <JournalTitle>Cancer Treat Rev</JournalTitle>
                <VolumeID>22</VolumeID>
                <FirstPage>289</FirstPage>
                <LastPage>331</LastPage>
                <Occurrence Type="PID">
                  <Handle>9025785</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0305-7372(96)90021-3</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXht12jtbk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Vinholes J, Coleman R, Eastell R. Effects of bone metastases on bone metabolism: implications for diagnosis, imaging and assessment of response to cancer treatment. Cancer Treat Rev 1996;22:289–331.</BibUnstructured>
            </Citation>
            <Citation ID="CR52_34">
              <CitationNumber>52</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RC</Initials>
                  <FamilyName>Percival</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GH</Initials>
                  <FamilyName>Urwin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Harris</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1987</Year>
                <ArticleTitle Language="En">Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption</ArticleTitle>
                <JournalTitle>Eur J Surg Oncol</JournalTitle>
                <VolumeID>13</VolumeID>
                <FirstPage>41</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>3102281</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaL2s7jsVaqtA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Percival RC, Urwin GH, Harris S, et al. Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. Eur J Surg Oncol 1987;13:41–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR53_34">
              <CitationNumber>53</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Zhang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Dai</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Qi</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone</ArticleTitle>
                <JournalTitle>J Clin Invest</JournalTitle>
                <VolumeID>107</VolumeID>
                <FirstPage>1235</FirstPage>
                <LastPage>44</LastPage>
                <Occurrence Type="PID">
                  <Handle>11375413</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1172/JCI11685</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXjsl2ntr0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Zhang J, Dai J, Qi Y, et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 2001;107:1235–44.</BibUnstructured>
            </Citation>
            <Citation ID="CR54_34">
              <CitationNumber>54</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>BI</Initials>
                  <FamilyName>Carlin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GL</Initials>
                  <FamilyName>Andriole</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>88</VolumeID>
                <FirstPage>2989</FirstPage>
                <LastPage>94</LastPage>
                <Occurrence Type="PID">
                  <Handle>10898342</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/1097-0142(20000615)88:12+&lt;2989::AID-CNCR14&gt;3.0.CO;2-Q</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD3czlsVOjtQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Carlin BI, Andriole GL. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer 2000;88:2989–94.</BibUnstructured>
            </Citation>
            <Citation ID="CR55_34">
              <CitationNumber>55</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Karsenty</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">Bone formation and factors affecting this process</ArticleTitle>
                <JournalTitle>Matrix Biol</JournalTitle>
                <VolumeID>19</VolumeID>
                <FirstPage>85</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>10842091</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0945-053X(00)00053-6</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXkt1aqurY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Karsenty G. Bone formation and factors affecting this process. Matrix Biol 2000;19:85–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR56_34">
              <CitationNumber>56</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AM</Initials>
                  <FamilyName>Parfitt</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">The mechanism of coupling: a role for the vasculature</ArticleTitle>
                <JournalTitle>Bone</JournalTitle>
                <VolumeID>26</VolumeID>
                <FirstPage>319</FirstPage>
                <LastPage>23</LastPage>
                <Occurrence Type="PID">
                  <Handle>10787232</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S8756-3282(00)80937-0</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD3c3ks1amtA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Parfitt AM. The mechanism of coupling: a role for the vasculature. Bone 2000;26:319–23.</BibUnstructured>
            </Citation>
            <Citation ID="CR57_34">
              <CitationNumber>57</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>BF</Initials>
                  <FamilyName>Boyce</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DE</Initials>
                  <FamilyName>Hughes</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KR</Initials>
                  <FamilyName>Wright</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Xing</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Dai</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">Recent advances in bone biology provide insight into the pathogenesis of bone diseases</ArticleTitle>
                <JournalTitle>Lab Invest</JournalTitle>
                <VolumeID>79</VolumeID>
                <FirstPage>83</FirstPage>
                <LastPage>94</LastPage>
                <Occurrence Type="PID">
                  <Handle>10068197</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK1M7msFGltA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Boyce BF, Hughes DE, Wright KR, Xing L, Dai A. Recent advances in bone biology provide insight into the pathogenesis of bone diseases. Lab Invest 1999;79:83–94.</BibUnstructured>
            </Citation>
            <Citation ID="CR58_34">
              <CitationNumber>58</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Pectasides</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Nikolaou</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Farmakis</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid</ArticleTitle>
                <JournalTitle>Anticancer Res</JournalTitle>
                <VolumeID>25</VolumeID>
                <FirstPage>1457</FirstPage>
                <LastPage>63</LastPage>
                <Occurrence Type="PID">
                  <Handle>15865105</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXkt1Wmsr4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Pectasides D, Nikolaou M, Farmakis D, et al. Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid. Anticancer Res 2005;25:1457–63.</BibUnstructured>
            </Citation>
            <Citation ID="CR59_34">
              <CitationNumber>59</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Vogelzang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Nelson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Schulman</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Meta-analysis of clinical trials of atrasentan 10 mg in metastatic hormone-refractory prostate cancer</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>23</VolumeID>
                <FirstPage>4563</FirstPage>
              </BibArticle>
              <BibUnstructured>Vogelzang N, Nelson J, Schulman C, et al. Meta-analysis of clinical trials of atrasentan 10 mg in metastatic hormone-refractory prostate cancer. J Clin Oncol 2005;23:4563.</BibUnstructured>
            </Citation>
            <Citation ID="CR60_34">
              <CitationNumber>60</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Carducci</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JB</Initials>
                  <FamilyName>Nelson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Saad</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Effects of atrasentan on disease progression and biological markers in men with metastatic hormone-refractory prostate cancer: phase 3 study</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>22</VolumeID>
                <FirstPage>4508</FirstPage>
              </BibArticle>
              <BibUnstructured>Carducci M, Nelson JB, Saad F, et al. Effects of atrasentan on disease progression and biological markers in men with metastatic hormone-refractory prostate cancer: phase 3 study. J Clin Oncol 2004;22:4508.</BibUnstructured>
            </Citation>
            <Citation ID="CR61_34">
              <CitationNumber>61</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PN</Initials>
                  <FamilyName>Lara</FamilyName>
                  <Suffix>Jr</Suffix>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WM</Initials>
                  <FamilyName>Stadler</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Longmate</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>12</VolumeID>
                <FirstPage>1556</FirstPage>
                <LastPage>63</LastPage>
                <Occurrence Type="PID">
                  <Handle>16533781</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1078-0432.CCR-05-2074</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XitVGms7c%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lara PN, Jr., Stadler WM, Longmate J, et al. A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases. Clin Cancer Res 2006;12:1556–63.</BibUnstructured>
            </Citation>
            <Citation ID="CR62_34">
              <CitationNumber>62</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Cristofanilli</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GT</Initials>
                  <FamilyName>Budd</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>Ellis</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Circulating tumor cells, disease progression, and survival in metastatic breast cancer</ArticleTitle>
                <JournalTitle>N Engl J Med</JournalTitle>
                <VolumeID>351</VolumeID>
                <FirstPage>781</FirstPage>
                <LastPage>91</LastPage>
                <Occurrence Type="PID">
                  <Handle>15317891</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1056/NEJMoa040766</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXntVeitb4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004;351:781–91.</BibUnstructured>
            </Citation>
            <Citation ID="CR63_34">
              <CitationNumber>63</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DF</Initials>
                  <FamilyName>Hayes</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Cristofanilli</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GT</Initials>
                  <FamilyName>Budd</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>12</VolumeID>
                <FirstPage>4218</FirstPage>
                <LastPage>24</LastPage>
                <Occurrence Type="PID">
                  <Handle>16857794</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1078-0432.CCR-05-2821</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XntFSms7Y%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hayes DF, Cristofanilli M, Budd GT, et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 2006;12:4218–24.</BibUnstructured>
            </Citation>
            <Citation ID="CR64_34">
              <CitationNumber>64</CitationNumber>
              <BibUnstructured>Moreno JSD, Shaffer D, Montgomery B, et al. Multi-center study evaluating circulating tumor cells (CTCs) as a surrogate for survival in men treated for castration refractory prostate cancer (CRPC). J Clin Oncol. 2007 ASCO Annual Meeting Proceedings Part I. 2007;25(20 Suppl):5016.</BibUnstructured>
            </Citation>
          </Bibliography>
        </ChapterBackmatter>
      </Chapter>
    </Part>
  </Book>
</Publisher>
